ANNOUNCEMENT

MedCity CONVERGE brings together the entire ecosystem to discuss Healthcare Innovation this July.

Topic: CELG

Former court foes Penn and pharma company forge cancer therapeutics licensing deal

Former court foes Penn and pharma company forge cancer therapeutics licensing deal

August 31, 2012 6:30 pm by | 0 Comments

An unusual lawsuit between the University of Pennsylvania, the university’s Abramson Cancer Center and Agios Pharmaceuticals over alleged intellectual property theft has been dropped and has been transformed into a ... Read more
Celgene’s multiple myeloma drug setback in Europe gets mixed response

Celgene’s multiple myeloma drug setback in Europe gets mixed response

June 21, 2012 2:57 pm by | 0 Comments

Celgene’s (NASDAQ:CELG) move to withdraw its multiple myeloma drug Revlimid new application submission from the Committee for Medicinal Products for Human Use was a setback for the drug developer. But ... Read more
Celgene submits NDA for multiple myeloma, forges personalized medicine collaboration

Celgene submits NDA for multiple myeloma, forges personalized medicine collaboration

April 26, 2012 1:43 pm by | 0 Comments

Celgene (NASDAQ:CELG) has submitted a new drug application to the U.S. Food and Drug Administration for pomalidomide, a drug designed for multiple myeloma that does not respond to therapies.Since the ... Read more
Celgene in strategic discovery deal with therapeutic antibody firm

Celgene in strategic discovery deal with therapeutic antibody firm

April 9, 2012 3:49 pm by | 0 Comments

Celgene (NASDAQ:CELG) has agreed to a strategic discovery deal with a company that is developing antibodies to combat multiple diseases in Celgene’s latest move to diversify its portfolio.AnaptysBio uses a ... Read more
Celgene invests $15 million for closer collaboration with cancer drug co.

Celgene invests $15 million for closer collaboration with cancer drug co.

February 9, 2012 11:27 am by | 0 Comments

Celgene (NYSE:CELG) has made a $15 million strategic investment in a cancer drug developer, which gives it a seat on the company’s board and opens up collaboration opportunities down the ... Read more
Celgene cancer drug acquisition may bode well for life science M&A

Celgene cancer drug acquisition may bode well for life science M&A

January 26, 2012 5:18 pm by | 0 Comments

Celgene (NYSE:CELG) has acquired cancer drug developer Avila Therapeutics in a deal valued up to $925 million if milestones are reached.Avila’s therapeutic platform involves the development of covalent drugs, which ... Read more
Penn cancer research institute sues former director over IP breach

Penn cancer research institute sues former director over IP breach

January 13, 2012 5:32 pm by | 0 Comments

The CEO of Memorial Sloane-Kettering Cancer Research Center is the focus of a $1 billion lawsuit filed by a cancer research institute at the University of Pennsylvania for allegedly stealing ... Read more
N.J. governor’s chief of staff will return to pharmaceutical industry

N.J. governor’s chief of staff will return to pharmaceutical industry

December 23, 2011 8:30 am by | 0 Comments

New Jersey Gov. Chris Christie’s chief of staff is returning to the pharmaceutical industry in a newly created position with Celgene (NASDAQ: CELG) next month.Richard Bagger will serve as senior ... Read more